# A Multicenter, Randomized, Double-blind, Placebo-controlled Trial on the Treatment of Hypertensive Intracerebral Hemorrhage With Naoxuekang Dropping Pills

Study · id `cardio:ct-nct07200921` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07200921](<https://clinicaltrials.gov/study/NCT07200921>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07200921

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1950 participants.

## Technical summary

Registry record NCT07200921. Randomized; quadruple masking; primary purpose treatment. Start 2025-10-10 (anticipated); primary completion 2028-11-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 1950 participants (planned count; ClinicalTrials.gov record NCT07200921, source copy `cardio:ctgov-nct07200921-2025-10-01`, retrieved 2026-11-18)
- Planned start: 2025-10-10 (anticipated) (ClinicalTrials.gov record NCT07200921, source copy `cardio:ctgov-nct07200921-2025-10-01`, retrieved 2026-11-18)
- Primary completion: 2028-11-30 (anticipated) (ClinicalTrials.gov record NCT07200921, source copy `cardio:ctgov-nct07200921-2025-10-01`, retrieved 2026-11-18)
- Completion: 2028-11-30 (anticipated) (ClinicalTrials.gov record NCT07200921, source copy `cardio:ctgov-nct07200921-2025-10-01`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07200921, source copy `cardio:ctgov-nct07200921-2025-10-01`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07200921-2025-10-01`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial on the Treatment of Hypertensive Intracerebral Hemorrhage With Naoxuekang Dropping Pills
- Acronym: TCM-ICH
- Condition: Hypertensive Intracerebral Hemorrhage
- Condition: Cerebral Small Vessel Diseases
- Intervention (Drug): Naoxuekang Dropping Pills
- Intervention (Drug): Naoxuekang Matching Placebo
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER
- Collaborator: The Affiliated Hospital of Qingdao University
- Collaborator class: OTHER
- Collaborator: Beijing Kangerfu Pharmaceutical Company Limited
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Cerebral small vessel disease (`cardio:cerebral-small-vessel-disease`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)
- Registry lists this organization as a collaborator: The Affiliated Hospital of Qingdao University (`cardio:org-the-affiliated-hospital-of-qingdao-university`)

## Provenance

Content hash: dd7083b0f5e091a57eca1496f180ae86a8f2668772daaa64267fd2a67964791c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
